Abstract
Chinese medicine (CM) in inhalation therapy has a long history of applications since ancient China in the forms of smoke, steam vapor, medicated pillows and aromatic sachets. Over the years, thousands of clinical treatments involving the inhalation of CMs have been reported for the treatment of respiratory disease. Shuanghuanglian, Yuxingcao and Qingkailing are primarily applied in pneumonia and bronchitis. At present, metered dose inhalation (MDI), aromatic inhalation and nebulized inhalation are used extensively in practice. In particular, nebulized CM for the treatment of respiratory diseases has been applied as a noninvasive route with reduced serious adverse reactions and is equivalent to or more efficacious than its intravenous counterparts. Although nebulized CM is widely used in clinical practice, only three MDI and five aromatic inhalations of CM products have been approved by the China Food and Drug Administration (CFDA), and no products in the form of a dry powder inhaler (DPI) or in dosage forms intended for nebulization have been reported. The development of formulations for CM has focused on improving the aerodynamic performance of the particles prepared by spray drying, enhancing the bioavailability and local concentration in the respiratory tract, and increasing the mucoadhesion and sustained release of the CM upon the incorporation of novel excipients. New devices, including MDI and nebulizer devices, have been developed for the delivery of the above-mentioned particles to the pulmonary system. Although the development of CM inhalation products to meet the international quality standards is facing a number of challenges, the inhalation of CMs show great potential for further exploration, particularly as an alternative route to IV infusion for the treatment of respiratory diseases.
Keywords: Chinese medicine, inhalation, nebulizer, pulmonary disease, shuanghuanglian, yuxingcao, qingkailing.
Current Pharmaceutical Design
Title:Chinese Medicine in Inhalation Therapy: A Review of Clinical Application and Formulation Development
Volume: 21 Issue: 27
Author(s): Xiaoqing Miao, Jing Zhou, Jian Li, Yonghong Liao and Ying Zheng
Affiliation:
Keywords: Chinese medicine, inhalation, nebulizer, pulmonary disease, shuanghuanglian, yuxingcao, qingkailing.
Abstract: Chinese medicine (CM) in inhalation therapy has a long history of applications since ancient China in the forms of smoke, steam vapor, medicated pillows and aromatic sachets. Over the years, thousands of clinical treatments involving the inhalation of CMs have been reported for the treatment of respiratory disease. Shuanghuanglian, Yuxingcao and Qingkailing are primarily applied in pneumonia and bronchitis. At present, metered dose inhalation (MDI), aromatic inhalation and nebulized inhalation are used extensively in practice. In particular, nebulized CM for the treatment of respiratory diseases has been applied as a noninvasive route with reduced serious adverse reactions and is equivalent to or more efficacious than its intravenous counterparts. Although nebulized CM is widely used in clinical practice, only three MDI and five aromatic inhalations of CM products have been approved by the China Food and Drug Administration (CFDA), and no products in the form of a dry powder inhaler (DPI) or in dosage forms intended for nebulization have been reported. The development of formulations for CM has focused on improving the aerodynamic performance of the particles prepared by spray drying, enhancing the bioavailability and local concentration in the respiratory tract, and increasing the mucoadhesion and sustained release of the CM upon the incorporation of novel excipients. New devices, including MDI and nebulizer devices, have been developed for the delivery of the above-mentioned particles to the pulmonary system. Although the development of CM inhalation products to meet the international quality standards is facing a number of challenges, the inhalation of CMs show great potential for further exploration, particularly as an alternative route to IV infusion for the treatment of respiratory diseases.
Export Options
About this article
Cite this article as:
Miao Xiaoqing, Zhou Jing, Li Jian, Liao Yonghong and Zheng Ying, Chinese Medicine in Inhalation Therapy: A Review of Clinical Application and Formulation Development, Current Pharmaceutical Design 2015; 21 (27) . https://dx.doi.org/10.2174/1381612821666150820110550
DOI https://dx.doi.org/10.2174/1381612821666150820110550 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc., has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-Based Biomarkers in Large-Scale Screening for Neurodegenerative Diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Diabetes Mellitus: Advances in Diagnosis and Treatment driving by Precision Medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Thyroid Diseases and their Medications in Cardiovascular Disorders: A Review of the Literature
Current Cardiology Reviews Potential Triazole-based Molecules for the Treatment of Neglected Diseases
Current Medicinal Chemistry Strategies for Enhancing Progenitor Cell Mobilization and Function in Diabetes
Current Vascular Pharmacology Fundamental Concepts of the Angiogenic Process
Current Molecular Medicine Fluoroquinolones: Blessings Or Curses
Current Drug Targets Oxidative RNA Damage and Neurodegeneration
Current Medicinal Chemistry Oxidative Stress Biomarkers in Coronary Artery Disease
Current Topics in Medicinal Chemistry Type 1 Diabetes Mellitus Clinical Profile and Follow-up: North Emirate Hospitals’ Experience
New Emirates Medical Journal Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Is the Therapeutic Potential of Stem Cells for Myocardial Regeneration Limited by Proarrhythmic Effects?
Current Cardiology Reviews Mechano-chemo-biological Computational Models for Arteries in Health, Disease and Healing: From Tissue Remodelling to Drug-eluting Devices
Current Pharmaceutical Design Atherosclerosis Potential Drug Targets: Current Scenario and Future Perspectives
Cardiovascular & Hematological Disorders-Drug Targets Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor
Cardiovascular & Hematological Agents in Medicinal Chemistry Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women
Current Pharmaceutical Design Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Editorial: (Thematic Issue: Autoimmune diseases: What have we learned from mice?)
Current Pharmaceutical Design Nanomedicine “New Food for an Old Mouth”: Novel Approaches for the Treatment of COVID-19
Drug Delivery Letters Nutrient Content of Lettuce and its Improvement
Current Nutrition & Food Science Myocardial Ischemia/Reperfusion Injury: Potential of TRPV1 Agonists as Cardioprotective Agents
Cardiovascular & Hematological Disorders-Drug Targets